PIRSのチャート
PIRSの企業情報
| symbol | PIRS |
|---|---|
| 会社名 | Pieris Pharmaceuticals Inc （ピエリス・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Commercial Physical_Biological Resarch |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ピエリス・ファーマセウティカルズ(Pieris Pharmaceuticals Inc.)は臨床段階のバイオ医薬品会社である。同社のパイプラインには、腫瘍の微小環境に合わせた免疫腫瘍学のマルチスペック、コントロールされていない喘息治療用のAnticalin、半減期最適化Anticalinが含まれる。同社のAnticalinsタンパク質は、リポカリンに由来する低分子量治療タンパク質のクラスである。そのリポカリンは血漿および他の体液中に典型的に見られる、天然に存在する低分子量のヒトタンパク質である。同社はPRS-080、PRS-060、PRS-300シリーズの3つの候補薬剤を開発する。そのPRS-080は、ヘプシジンを標的とするアンタリチン薬候補である。2番目のアンタリチン薬候補であるPRS-060は、IL-4受容体α鎖（IL-4RA）と結合し、喘息および他の炎症性疾患を引き起こす炎症性カスケードにおけるメディエータであることが知られている2つのサイトカインIL-4およびIL-13の作用を阻害する。PRS-343はAnticalinベースの薬剤候補である。 ピエリス・ファ―マシュ―ティカルズはドイツのバイオ医療企業。同社は「Anticalin」クラスのバイオ・テクノロジ―を開発。臨床ステ―ジで、貧血症、ぜんそく、伝染病などに対する治療法の開発に従事し、パイプラインには「PRS-080」、「PRS-060」がある。また、免疫療法によるがん治療に取り組み、「PRS-343」、「PRS-050」を開発する。 pieris pharmaceuticals is a clinical stage biotechnology company that discovers and develops anticalin-based drugs to target validated disease pathways in a unique and transformative way. our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled anticalin to treat uncontrolled asthma and a half-life-optimized anticalin to treat anemia. proprietary to pieris, anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. our libraries of more than 100 billion different anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets. pieris has established a diverse pipeline of anticalin therapeutics for a number of different indications and has r&d collaborations with roche |
| 本社所在地 | 255 State Street 9th Floor Boston MA 02109 USA |
| 代表者氏名 | James A. Geraghty ジェームズ・A.グラガッティ |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 857-246-8998 |
| 設立年月日 | 41395 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 68人 |
| url | www.pieris.com |
| nasdaq_url | https://www.nasdaq.com/symbol/pirs |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -8.61440 |
| 終値（lastsale） | 5.045 |
| 時価総額（marketcap） | 272605006.005 |
| 時価総額 | 時価総額（百万ドル） 280.98040 |
| 売上高 | 売上高（百万ドル） 37.92184 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 130.00540 |
| 当期純利益 | 当期純利益（百万ドル） -8.48539 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Pieris Pharmaceuticals Inc revenues increased from $3.2M to $15.8M. Net loss decreased 51% to $8.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Other (expense) income net increase from $1.4M (expense) to $327K (income) Interest income increase from $0K to $987K (income). |
PIRSのテクニカル分析
PIRSのニュース
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference 2023/06/02 20:38:00 Finanz Nachrichten
BOSTON, MA / ACCESSWIRE / June 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® techno…
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference 2023/06/02 20:30:00 Wallstreet:Online
BOSTON, MA / ACCESSWIRE / June 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory and cancer diseases, …
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference 2023/05/22 12:02:00 Finanz Nachrichten
BOSTON, MA / ACCESSWIRE / May 22, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® techno…
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference 2023/05/22 12:00:00 Wallstreet:Online
BOSTON, MA / ACCESSWIRE / May 22, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and …
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference 2023/05/21 12:14:00 Finanz Nachrichten
BOSTON, MA / ACCESSWIRE / May 21, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® techno…
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022/09/08 20:01:00 Wallstreet:Online
BOSTON, MA / ACCESSWIRE / September 8, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer …
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS 2022/08/24 12:08:00 Finanz Nachrichten
BOSTON, MA / ACCESSWIRE / August 24, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® tec…
Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS 2022/08/24 12:00:00 Wallstreet:Online
BOSTON, MA / ACCESSWIRE / August 24, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, …
Pieris Pharmaceuticals''s Return On Capital Employed Insights 2022/08/19 14:18:19 Benzinga
Benzinga Pro data, Pieris Pharmaceuticals (NASDAQ: PIRS ) reported Q2 sales of $3.70 million. Earnings fell to a loss of $10.34 million, resulting in a 102.67% decrease from last quarter. Pieris Pharmaceuticals collected $10.99 million in revenue during Q1, but reported earnings showed a $5.10 million loss. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign … Full story available on Benzinga.com
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2022 Results - Earnings Call Transcript 2022/08/06 21:14:03 Seeking Alpha
Pieris Pharmaceuticals, Inc. (NASDAQ:NASDAQ:PIRS) Q2 2022 Results Conference Call August 04, 2022 08:00 AM ET Company Participants Tom Bures - Chief Financial Officer Steve Yoder -…
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022/09/08 20:01:00 Wallstreet:Online
BOSTON, MA / ACCESSWIRE / September 8, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer …
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS 2022/08/24 12:08:00 Finanz Nachrichten
BOSTON, MA / ACCESSWIRE / August 24, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® tec…
Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS 2022/08/24 12:00:00 Wallstreet:Online
BOSTON, MA / ACCESSWIRE / August 24, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, …
Pieris Pharmaceuticals''s Return On Capital Employed Insights 2022/08/19 14:18:19 Benzinga
Benzinga Pro data, Pieris Pharmaceuticals (NASDAQ: PIRS ) reported Q2 sales of $3.70 million. Earnings fell to a loss of $10.34 million, resulting in a 102.67% decrease from last quarter. Pieris Pharmaceuticals collected $10.99 million in revenue during Q1, but reported earnings showed a $5.10 million loss. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign … Full story available on Benzinga.com
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2022 Results - Earnings Call Transcript 2022/08/06 21:14:03 Seeking Alpha
Pieris Pharmaceuticals, Inc. (NASDAQ:NASDAQ:PIRS) Q2 2022 Results Conference Call August 04, 2022 08:00 AM ET Company Participants Tom Bures - Chief Financial Officer Steve Yoder -…